Breast Cancer in Women Aged 75 Years and Older

Basit Öğe Kaydı
dc.contributor.authorBulut, Gülcan
dc.contributor.authorYavuz, Burcu Balam
dc.contributor.authorKaraca, Burçak
dc.contributor.authorGüner, Merve
dc.contributor.authorAlmuradova, Elvina
dc.date.accessioned2023-01-12T20:32:05Z
dc.date.available2023-01-12T20:32:05Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractObjective: Breast cancer is the most common cancer in women, with incidence and mortality increasing dramatically with age. Applying data ofyounger patients to the geriatric age group indicates ‘‘evidence biased medicine’’. Therefore, this study aimed to present the clinical and pathologicalfeatures of breast cancer and treatment choices in older patients.Materials and Methods: This study included 72 patients aged 75 years and older with breast cancer who were admitted to our medical oncologyclinic between 2005 and 2013. Clinicopathological and demographic features, progression-free survival and overall survival and adjuvant andpalliative treatments were recorded retrospectively. Categorical variables were presented as number (n) and percentage (%) and continuous variablesas median and minimum-maximum. Survival curves were drawn using the Kaplan-Meier method. P<0.05 was considered as statistically significant.Results: The study population consisted of 72 patients, with a median age of 78 (minimum-maximum: 75-88). The most common pathologicaltype of breast cancer was invasive ductal carcinoma, followed by infiltrative lobular carcinoma. Steroid receptor positivity rates were high, and thecerbB2 status was mostly negative; older patients had favourable tumours. Endocrine therapy was the most preferred option in this geriatric patientgroup, and aromatase inhibitors were the most commonly chosen hormonotherapy. Endocrine therapy is the first choice in palliative treatment;however, chemotherapy was preferred in second- and third-line treatment in metastatic diseases.Conclusion: According to available literature, geriatric patients show similarities in histologic and intrinsic subtypes with postmenopausal women,except for frailty and comorbidities. However, in geriatric patients, endocrine therapy is preferred as adjuvant and/or metastatic treatment becausethey are more susceptible to chemotherapeutic agents. Oncologists should consulate every older patient to geriatric medicine, and comprehensivegeriatric assessment should be done to decide and continue treatment. Age should not be the only factor in decision-making.en_US
dc.identifier.doi10.4274/ejgg.galenos.2020.413
dc.identifier.endpage123en_US
dc.identifier.issn2687-2625
dc.identifier.issue2en_US
dc.identifier.startpage117en_US
dc.identifier.trdizinid445642en_US
dc.identifier.urihttps://doi.org/10.4274/ejgg.galenos.2020.413
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/445642
dc.identifier.urihttps://hdl.handle.net/11454/81019
dc.identifier.volume3en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofEuropean journal of geriatrics and gerontology (Online)en_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleBreast Cancer in Women Aged 75 Years and Olderen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu